The firm noted Moderna's reduced 2024 sales forecast of $3.0–$3.1 billion, down from $3.0–$3.5 billion, driven by declines in Spikevax (COVID vaccine) sales and minimal contributions from ...

One key concern is the near-term uncertainty in Moderna’s commercial respiratory vaccine ... strategic priorities such as driving the use of Spikevax and mResvia, seeking 10 product approvals ...

Pharmacist Kim Nguyen administers a Moderna Spikevax COVID-19 vaccine at a CVS, Wednesday, Sept. 20, 2023, in Cypress, Texas. Weak adoption of Moderna’s respiratory syncytial virus (RSV ...

Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or ...